Media headlines about BioMarin Pharmaceutical (NASDAQ:BMRN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.9322570586966 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
BMRN traded down $0.30 during midday trading on Friday, hitting $83.59. 1,402,827 shares of the company were exchanged, compared to its average volume of 1,275,847. The company has a market capitalization of $14,770.71, a PE ratio of -124.76 and a beta of 1.69. BioMarin Pharmaceutical has a 1-year low of $75.81 and a 1-year high of $100.51. The company has a current ratio of 2.70, a quick ratio of 2.12 and a debt-to-equity ratio of 0.29.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.06). The company had revenue of $358.31 million for the quarter, compared to analyst estimates of $346.24 million. BioMarin Pharmaceutical had a negative return on equity of 3.18% and a negative net margin of 8.91%. equities research analysts predict that BioMarin Pharmaceutical will post -0.16 EPS for the current fiscal year.
BMRN has been the topic of a number of research reports. Goldman Sachs upgraded BioMarin Pharmaceutical from a “buy” rating to a “conviction-buy” rating in a research report on Friday, December 15th. JPMorgan Chase restated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Sunday, February 25th. BidaskClub lowered BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 20th. Zacks Investment Research upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $101.00 price objective on the stock in a research report on Tuesday, January 16th. Finally, Credit Suisse Group restated a “buy” rating and set a $113.00 price objective on shares of BioMarin Pharmaceutical in a research report on Sunday, February 25th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $112.34.
In other news, EVP George Eric Davis sold 2,105 shares of the business’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $79.04, for a total value of $166,379.20. Following the transaction, the executive vice president now directly owns 90,089 shares of the company’s stock, valued at approximately $7,120,634.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey Robert Ajer sold 1,537 shares of the business’s stock in a transaction dated Thursday, March 29th. The shares were sold at an average price of $79.69, for a total value of $122,483.53. Following the completion of the transaction, the executive vice president now directly owns 55,033 shares in the company, valued at $4,385,579.77. The disclosure for this sale can be found here. Insiders have sold a total of 85,269 shares of company stock worth $7,301,002 over the last ninety days. Company insiders own 1.85% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/15/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-biomarin-pharmaceutical-bmrn-stock-price.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.